Insilico Medicine, a Hong Kong-based AI company, has announced a new collaboration with Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) aimed at improving care for breast cancer patients.
CTFH, a pharmaceutical company known for adopting advanced technologies, is a joint venture between the Chia-Tai Group and Jiangsu Agriculture Reclamation Group. The work by Insilico Medicine and CTFH will be focused on accelerating “drug discovery and development with an AI-enabled platform for triple-negative breast cancer.”
“We look forward to a long-term partnership with Insilico Medicine,” Wenyu Xia, general manager of CTFH, said in a prepared statement. “As the premier AI drug discovery company in the industry, Insilico Medicine has demonstrated capabilities to generate novel molecules with specified properties using its next-generation AI platform. We believe that this collaboration will speed up the R&D process, reduce the cost and provide greater benefits to patients.”
Insilico Medicine could receive up to $200 million for its efforts if certain key milestones are reached.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.